▶ The Retatrutide Decision: Wait, Switch, or Start Now? — a 6-minute, plain-English explainer.
28.3%
Phase 3 Weight Loss (Claimed)
12 mg dose at 80 weeks · TRIUMPH-1 press release, May 2026 — not yet peer-reviewed
0
Independent Phase 3 Publications
All Phase 3 numbers so far come from Lilly's own press releases
~20-40%
Of Weight Lost Is Lean Mass
Phase 2 DEXA data · muscle, not just fat
$1,000-1,400
Projected Monthly List Price
Estimated from Lilly's existing Zepbound/Wegovy pricing — not yet set
Follow the Money
Who ProfitsBefore the numbers: know who is telling you the numbers, and what they stand to gain. This isn't a conspiracy claim — it's the plain business reality behind every headline on this drug.
The Sponsor Runs the Trial
Lilly × 5
Every TRIUMPH trial is designed, funded, run, and analyzed by Eli Lilly — the company that will sell the drug. The academic co-authors (Jastreboff, Kaplan, etc.) are compensated consultants/investigators on Lilly-sponsored protocols, not independent auditors. That's standard for drug trials — but it means every number on this page traces back to the company with the most to gain from a good result.
The Franchise At Stake
$13B+/yr
Lilly's existing GLP-1 franchise (Zepbound + Mounjaro) posted more than $13 billion in 2025 sales. Retatrutide is explicitly positioned by Lilly's own investor materials to extend that franchise and beat competitor Novo Nordisk. The May 2026 "topline" announcement was released as an investor press release, not a peer-reviewed paper — that's the audience it was built for first.
No Independent Replication Yet
Press Release ≠ Paper
The 28.3% / 30.3% numbers everywhere in the news are from Lilly's own topline release. As of this page's date, full Phase 3 data has not passed independent peer review or been published in a journal — the Pharmaceutical Journal specifically flagged that the safety data "deserve careful scrutiny once peer-reviewed." Treat the headline numbers as the sponsor's claim until that happens.
Patent = No Cheap Competitor
Locked In
Retatrutide is patented; Lilly is the only company that can sell it. Unlike a generic, there's no future price competition coming. Compare: semaglutide and tirzepatide, both patented and both from single manufacturers, already run $150-1,349/month uninsured — and insurers are actively dropping GLP-1 coverage as costs climb.
Head-to-Head: Weight Loss vs Alternatives
PubMed · Sponsor Press ReleaseThe trial numbers are genuinely large — approaching what bariatric surgery delivers, without surgery. That's real and worth reporting straight. But two of these four bars (semaglutide, tirzepatide) are peer-reviewed, published, FDA-approved numbers; the retatrutide bar is Lilly's own unreviewed press-release figure. Hold that difference in mind while you look at the chart.
Mechanism: Three Receptors, Three Effects
PubMed · PharmacologySemaglutide hits one receptor. Tirzepatide hits two. Retatrutide hits all three of the gut-hormone receptors at once — and the third (glucagon) is the mechanism Lilly credits for the larger weight-loss claim. Here's what each receptor does, including the side effect the glucagon piece brings with it.
GLP-1 Receptor
Appetite ↓
Suppresses appetite by acting on hypothalamic satiety circuits. Slows gastric emptying — food stays in the stomach longer, you feel full faster. Glucose-dependent insulin release from the pancreas (no hypoglycemia risk). This is what semaglutide (Wegovy / Ozempic) hits alone.
GIP Receptor
Insulin ↑
Potentiates insulin secretion when glucose is rising. Modulates fat storage and central appetite signals — the exact CNS role is still being mapped. Tirzepatide (Zepbound / Mounjaro) hits this PLUS GLP-1.
Glucagon Receptor
Energy ↑
Increases energy expenditure — the body burns more calories at rest. Mobilizes liver fat. This is the third lever retatrutide adds — and glucagon receptor activity is also the leading suspected driver of the heart-rate side effect below. More mechanism isn't automatically better; it's also more places for something to go wrong.
Cardiac Side Effect
+6.7 bpm
Dose-dependent resting heart-rate increase, largest of any GLP-1-class drug tested. Peaks ~24 weeks, only partially declines after. Larger than tirzepatide (~2-3 bpm) or semaglutide (~3-4 bpm). No long-term cardiac outcome data exists yet for this drug specifically — the TRIUMPH-Outcomes cardio-kidney trial won't read out for years.
Published & Ongoing Human Trials
PubMed · Clinical RCTsRetatrutide does have real Phase 2 randomized data — double-blind, placebo-controlled, published in a peer-reviewed journal. That's genuinely more than many hyped compounds can claim. The Phase 3 program is large, but as of this page's date its only public results are Lilly's own topline press releases, not published papers.
| # | Study | Phase | n | Outcome (12 mg unless noted) |
|---|---|---|---|---|
| 1 |
Phase 2 NEJM — Adults with Obesity (Jastreboff et al.)
|
Phase 2 RCT · Peer-reviewed | 338 | -24.2% body weight at 48 wk (vs -2.1% placebo) |
| 2 |
Phase 2 Body Composition Substudy (T2D, DXA-measured)
|
Phase 2 substudy · Peer-reviewed | 189 | -26.1% total fat mass, but ~20-25% of ALL weight lost was lean/fat-free mass |
| 3 |
TRIUMPH-1 — Phase 3 Obesity (Topline May 21, 2026)
|
Phase 3 RCT · Sponsor topline only | ~2,000 | Claimed: -28.3% body weight at 80 wk · -30.3% at 104 wk — unverified by independent review |
| 4 |
TRIUMPH-2, -3, -4 — OSA, CVD, Knee OA basket trials
|
Phase 3 RCT | ~3,800 | Ongoing · readouts 2026-2028 |
| 5 |
TRANSCEND-CKD — Phase 2b Kidney Disease
|
Phase 2b RCT | 146 | Ongoing · primary endpoint at 24 wk (mGFR) |
Reality check: Every trial in this table is designed, funded, and run by Eli Lilly — the company that will sell this drug. That's standard pharma practice, not unique to retatrutide, but it means there is currently zero independently-run or independently-funded human trial data on this molecule. The Phase 3 program has enrolled 5,800+ participants — a genuinely large program — but "large" and "independently verified" are different claims. No long-term (multi-year) safety data exists for any dose.
Muscle Loss & What the Trials Don't Tell You Yet
PubMed · Independent ReviewsThis is the honest gap in the retatrutide story that the headline weight-loss number hides. Independent (non-Lilly) reviews of the entire GLP-1/GIP/glucagon drug class — not paid for by any drugmaker — have raised this directly.
Lean Mass Loss
~20-25%
In the one published DEXA (body-composition) substudy, roughly 20-25% of all weight lost was fat-free mass — not fat. That includes muscle. A Harvard Medical School review (independent of Lilly) of the whole incretin-drug class found weight loss from these drugs "typically comes from fat mass, but... also results in the loss of lean mass, including muscle," and flagged a real risk of drug-induced sarcopenia (muscle-wasting).
Without Resistance Training
Up to 40%
Analysis of the broader GLP-1 drug class found that without a structured resistance-training program, up to 40% of the weight lost on these drugs can be lean mass — comparable to a decade or more of age-related muscle decline compressed into months. A Diabetes Care review (University of Western Australia, non-Lilly) concluded resistance exercise should be a required adjunct, not an afterthought.
No Phase 3 Body-Composition Data Yet
Unpublished
Lilly's May 2026 topline release reported total weight loss — it did not break out how much was fat versus muscle at Phase 3 scale. Independent clinicians reviewing the announcement noted this gap directly: the Phase 2 substudy is the best public data available, and it already showed meaningful lean-mass loss. Until Lilly publishes Phase 3 DEXA data, the muscle-loss question for the actual 28.3% figure is genuinely unanswered.
Sarcopenia Risk Named Directly
"Vital Strategy"
A 2025 review titled "Saving muscle while losing weight" — written by exercise-medicine researchers in Croatia and Italy, no pharma funding disclosed — states plainly that muscle loss on these drugs "may contribute to difficulties in maintaining weight over the long term and can lead to sarcopenia," and calls preserving muscle mass a design priority these drugs have not solved.
Cost vs Weight-Loss Alternatives — Who Can Actually Get This
Market Data · US 2026If you're treating clinically meaningful obesity (BMI ≥30, or ≥27 with weight-related comorbidities), what are the real options and what do they actually cost? This is where the "miracle drug" framing runs into reality: only 13 US states currently mandate insurance coverage for GLP-1-class drugs used for obesity, and employers are actively dropping coverage as costs climb.
Free + Foundational
Diet + Exercise
$0
at minimum, no drug
3-5% weight loss typical
Required adjunct to any drug therapy — and the only defense against lean-mass loss on any of these drugs
Required adjunct to any drug therapy — and the only defense against lean-mass loss on any of these drugs
Semaglutide (Wegovy)
$150-1,349
/ month · compounded vs list
14.9% weight loss @ 68 wk
GLP-1 single agonist · FDA-approved, peer-reviewed
GLP-1 single agonist · FDA-approved, peer-reviewed
Tirzepatide (Zepbound)
$349-499
/ month · Lilly direct, cash
22.5% weight loss @ 72 wk
GLP-1 + GIP dual · FDA-approved, peer-reviewed
GLP-1 + GIP dual · FDA-approved, peer-reviewed
Not Yet Approved
Retatrutide (TBD brand)
Not retail
projected $1,000-1,400/mo, same range as Wegovy list price
28.3% weight loss (claimed) @ 80 wk
FDA approval, if granted, expected 2027-2028
FDA approval, if granted, expected 2027-2028
Permanent
Bariatric Surgery
$15K-25K
one-time, often covered
25-35% weight loss at 1-2 yr
Sleeve, bypass, SADI-S
Sleeve, bypass, SADI-S
Access reality: Nearly half of GLP-1 patients discontinue therapy over insurance barriers — prior authorizations, lost manufacturer coupons, or plans that simply exclude weight-loss indications. When patients stop, most of the weight comes back: one meta-analysis found roughly two-thirds of lost weight returns after discontinuation. A drug you can't afford to stay on isn't a cure — it's a subscription, and retatrutide is expected to launch at or above today's most expensive GLP-1 list prices.
Trial Dosing Protocol
PubMed · Phase 2/3 ProtocolsRetatrutide is a once-weekly subcutaneous injection with a ~6-day half-life. All trials use a dose-escalation schedule — starting low and stepping up monthly — specifically to reduce the GI side effects that knock 12-18% of patients out of treatment. No retail dose exists yet because FDA approval is pending; these are the trial protocols, run and funded by the drug's manufacturer.
Maintenance Doses
4 mg / 9 mg / 12 mg
Once-weekly subcutaneous injection · three dose strengths tested in Phase 3 TRIUMPH-1, all three claimed to hit endpoints per Lilly's topline release
Dose Escalation
2 → 4 → 8 → 12 mg
Monthly step-up. Lower starting dose (2 mg vs 4 mg) reduces nausea / vomiting / diarrhea peaks. Mandatory in trial design.
Treatment Duration
Chronic · ongoing
48 weeks (Phase 2) · 80 weeks (Phase 3 primary) · 104 weeks (continued) · Obesity is a chronic disease — the drug is taken indefinitely, not cycled. No trial has yet run past ~2 years, so multi-year safety and durability are unknown.
Critical Caveat
Investigational drug
Not FDA-approved. Cannot be legally prescribed in the U.S. except through enrolled clinical trial or documented compassionate-use exception. Any retail "retatrutide" sold today is gray-market compounded peptide with unverified purity — not the Lilly molecule used in TRIUMPH.
Regulatory & Access Status
T1 · Official AgenciesFDA (USA)
Not Approved — Phase 3, No NDA Filed
No New Drug Application has been filed. Phase 3 TRIUMPH-1 topline announced positive May 21, 2026, but that was Lilly's own release — not an FDA action. Earliest plausible NDA filing is Q4 2026; realistic approval window is 2027-2028, and FDA review could also request more safety data given the size of the heart-rate signal and the lean-mass gap.
Eli Lilly — Sponsor & Seller
Interested Party, Not a Regulator
Topline May 21, 2026: Lilly says all three doses met primary and key secondary endpoints. This is the manufacturer describing its own unreviewed data to investors, not a neutral safety verdict. Lilly trades as LLY on NYSE; the full TRIUMPH program (5 trials) is entirely Lilly-designed and Lilly-funded, continuing through 2026-2028. There is currently no independently-run trial of this molecule anywhere.
WADA / Sports
Will be banned on approval
Every GLP-1-class drug is treated as a Prohibited Substance for competitive athletes via WADA's "Metabolic Modulators" / "Non-Approved Substances" categories. Retatrutide will follow on FDA approval. Not a current concern for non-competitive users.
Compounding Status
Gray-Market — Buyer Beware
"Retatrutide" sold today by research-peptide vendors is NOT the Lilly molecule from TRIUMPH. It's a compounded approximation with unverified purity and unverified dose — and doctors are reportedly prescribing it off-label anyway before FDA review, according to independent reporting. Lilly holds the patent; only Lilly has access to the actual investigational compound until FDA approval.
The Investigators Behind the Data
Academic · Lilly-Sponsored Trials
These are the academic physicians who designed and ran the Lilly-funded trials. They are credentialed, real researchers — and also paid consultants/investigators on the sponsor's protocols. Both things are true at once; read their findings with that in mind.
Dr. Ania M. Jastreboff, MD, PhD
PI · Phase 2 + 3
First author on the Lilly-funded Phase 2 NEJM trial that reported retatrutide's 24.2% weight loss at 48 weeks (n=338). Principal investigator on the Lilly-sponsored Phase 3 TRIUMPH-1 trial. Director, Yale Obesity Research Center; Professor of Medicine (Endocrinology) and Pediatrics at Yale School of Medicine. Yale's investigator-disclosure standards require her to report consulting/research ties to Lilly and other GLP-1 manufacturers — standard for the field, and worth knowing when reading her public statements about the drug class.
Dr. Lee M. Kaplan, MD, PhD
TRIUMPH Design
Co-investigator on the Lilly-funded Phase 2 NEJM trial. Co-author on the TRIUMPH program design paper (Diabetes Obes Metab, 2025), the basket-trial methodology Lilly is using to evaluate retatrutide for obesity, sleep apnea, and knee osteoarthritis simultaneously. Director, Obesity and Metabolism Institute; faculty at Harvard Medical School / Massachusetts General Hospital.
Eli Lilly Research Team
LY3437943
The Lilly molecular team (Coskun, Bunck, Haupt, Milicevic, Hartman, Harris) designed retatrutide as a synthetic triple agonist with a ~6-day half-life. They are senior authors on the Phase 2 body-composition substudy (Lancet Diabetes Endocrinol, 2025) — the same paper showing meaningful lean-mass loss alongside the fat-loss headline. Lilly employees authoring the study that evaluates Lilly's own drug is normal industry practice — and a direct conflict of interest to weigh.
Dr. Christos S. Mantzoros, MD, DSc
Independent Reviewer
Not a TRIUMPH investigator. Senior author on independent reviews of the whole obesity-drug pipeline, including a 2024 Metabolism paper flagging that fat-free mass loss "is often overlooked" across ALL incretin drugs, retatrutide included, and can "impair metabolic health and increase the risk of subsequent sarcopenic obesity." Professor of Medicine, Harvard Medical School; Editor-in-chief of Metabolism. His group is the closest thing on this page to a non-Lilly voice with deep expertise in this drug class.
Community Voices & User Reports
Anecdotal · Real-World Voices
This section is anecdotal — intentionally. The trial data above is the science, and even that is sponsor-reported for Phase 3. This section is what real people inside the trials and outside them are actually saying. Positive AND negative voices are included on purpose. Not controlled, not blinded — included for honest context.
Dr. Ashley Froese, MD
Independent MD
A non-Lilly, non-academic voice on this drug class. Board-certified family-medicine physician running a Direct Primary Care clinic (Mesa, AZ) and the This Is Not Covered peptide-education channel. She covers the GLP-1 / peptide weight-loss class — mechanism, dosing logic, safety, and the gray-market compounding reality — independent of any drugmaker. Her consistent themes: these are chronic treatments, not quick fixes, and the gap between clean trial data and unverified compounded sourcing is the real-world risk. (Covers the class broadly; no retatrutide-specific published statement located as of this page's date.)
Trial Participants — Positive
76.7% Goal-Met
Published qualitative exit-interview study of 36 Phase 2 trial participants on retatrutide. 76.7% reported achieving their weight-reduction goal, described eating less often (n=31), feeling more in control of eating, improvements in mobility (n=27), energy levels (n=24), social activities (n=18), exercise (n=19), and clothing size (n=24). Most reported feeling more self-confident (n=32) and happy (n=25). Real reported benefit — shown here at full weight, not buried.
Trial Participants — Frustrations
3 of 36
From the SAME peer-reviewed exit-interview study — three participants reported frustration due to disappointing weight loss that didn't meet expectations. Two reported reduced social participation from adverse events; another two from new eating habits. Not everyone wins, even inside a Lilly-run trial with monitored care and a strong incentive to report success.
Compounded Retatrutide Users
$50-70/mo
The reality outside the trial: most people accessing “retatrutide” in 2026 are buying lyophilized peptide powder from research-peptide vendors at $50-70/month, with no prescription and no Lilly quality controls. Purity is unverified — the molecule may be genuine but the manufacturing chain isn't. Real anecdotal weight-loss reports exist; so do reports of injection-site reactions, dosing errors, and counterfeit product. This gray market exists precisely because the real drug is patented, unapproved, and priced out of reach for most people.
STAT News — Critical Reporting
18.2% Quit
Independent biomedical journalism flagged the 18.2% discontinuation rate at the 12 mg dose beneath the headline efficacy numbers. Lilly attributed some discontinuations to “perceived excessive weight loss” — the company's own framing of its own unfavorable data point. STAT also separately reported that Lilly gave a 79-year-old patient unusual "compassionate use" access to the unapproved drug outside a normal trial — the kind of access most patients don't have.
New to Retatrutide? Start Here.
Retatrutide is Eli Lilly's investigational triple-receptor injectable — one shot a week, three gut-hormone receptors hit at once, and a claimed 28.3% body-weight loss at the top dose in Phase 3. It's not on the market. It's not independently peer-reviewed yet. And the trial data that exists shows meaningful muscle loss alongside the fat loss. Here's the full picture in plain English — not the ad version.
What it is
A once-weekly injectable drug developed and owned by patent by Eli Lilly (also called LY3437943). It's a triple-receptor agonist — one molecule activating GLP-1, GIP, and glucagon receptors at once. Currently in Phase 3 trials, all funded and run by Lilly. Not FDA-approved.
What it does — and costs
Suppresses appetite, boosts insulin response, and increases resting calorie burn. The claimed Phase 3 result: 28.3% average body-weight loss at 80 weeks — from Lilly's own unreviewed press release. Independent body-composition data on the earlier, smaller trial shows roughly a fifth to a quarter of that lost weight was muscle, not fat.
How it's given
One subcutaneous injection per week. Dose escalation over several months: 2 mg → 4 mg → 8 mg → 12 mg, stepping up monthly to manage nausea. Treatment is chronic — ongoing, not a finite cycle. Stopping typically leads to weight regain, as with every other drug in this class.
Can I get it?
Not legally, not yet. Retatrutide is not FDA-approved; the only documented ways to access the real Lilly molecule are an enrolled clinical trial or a rare compassionate-use exception. The "retatrutide" sold by gray-market peptide vendors is NOT the Lilly molecule — it's compounded with unverified purity, and some doctors are reportedly prescribing it off-label ahead of approval.
What to weigh, not a verdict
The trial numbers are real and large. So are the open questions: no independent peer review of Phase 3 yet, no long-term safety data, meaningful lean-mass loss in the data that does exist, a manufacturer with $13B/year riding on a positive story, and a likely price tag matching or exceeding today's most expensive GLP-1 drugs. Whether that trade is worth it is a decision for you and a doctor who isn't selling the drug — not something this page decides for you.
Common Questions, Honest Answers
The questions people actually ask when they first hear about retatrutide. Answers grounded in the published data where it exists, and flagged clearly where it's sponsor-only.
How does this compare to Ozempic / Wegovy?
Same drug class (gut-hormone agonist), different math. Semaglutide (Ozempic / Wegovy) hits one receptor (GLP-1) and produces ~14.9% weight loss at 68 weeks — peer-reviewed, published, FDA-approved. Retatrutide's claimed 28.3% at 80 weeks is roughly double, but that number has not cleared independent peer review yet. Both are once-weekly subcutaneous injections.
And vs. Zepbound / Mounjaro (tirzepatide)?
Tirzepatide hits two receptors (GLP-1 + GIP) and produces a peer-reviewed ~22.5% weight loss. Retatrutide adds the glucagon receptor, which Lilly credits for the extra ~6 percentage points — and which is also the leading suspected cause of retatrutide's larger heart-rate side effect. Tirzepatide is approved, published, and available now; retatrutide is neither approved nor independently verified.
When can I actually get a prescription?
Eli Lilly is expected to file the New Drug Application with the FDA in Q4 2026 or early 2027. Standard FDA review takes 10-12 months. Earliest realistic retail availability: late 2027, more likely 2028 — and that assumes the FDA doesn't request additional safety data on the heart-rate signal or lean-mass loss, which is possible given how new the finding is at this dose.
What are the side effects?
Same class signature as other GLP-1 drugs — dose-related and mostly GI: nausea, vomiting, diarrhea, constipation, abdominal discomfort. Specific to retatrutide: the largest resting heart-rate increase (~6.7 bpm) of any drug in this class, and — not yet fully quantified at Phase 3 scale — meaningful lean/muscle mass loss alongside the fat loss. No multi-year safety data exists for any dose.
How many people quit because of side effects?
Per Lilly's own topline release: 12.2% at the 9 mg dose and 18.2% at the 12 mg dose discontinued, vs 4% on placebo. Lilly attributed some of that to “perceived excessive weight loss” — the manufacturer's own explanation of its own unfavorable number. That may be partly true and is also exactly the framing you'd expect from the party selling the drug.
How much weight will I lose, and how much of it is muscle?
Per Lilly's Phase 3 topline: 28.3% of starting body weight at 12 mg over 80 weeks, unverified by independent review. The one published body-composition substudy (smaller, earlier trial) found roughly 20-25% of total weight lost was lean/fat-free mass, and independent reviewers note that without resistance training, lean-mass loss across this drug class can run as high as 40%. Lilly has not published a Phase 3-scale breakdown of fat vs. muscle loss as of this page's date.
Will the weight stay off if I stop?
Probably not. Obesity is a chronic disease, and like blood pressure medication, stopping typically leads to weight regain. A meta-analysis of GLP-1-class discontinuation found roughly two-thirds of lost weight returns after stopping. Retatrutide is expected to follow the same pattern — meaning the real cost of this drug is the cost of staying on it indefinitely, not a one-time price.
Does it work for type 2 diabetes too?
The Phase 2 program included diabetic participants and showed strong HbA1c reductions plus body-fat-mass loss of -26.1% at the 8 mg dose — alongside the lean-mass loss noted in that same substudy. The Phase 3 TRIUMPH program is primarily obesity-focused but includes a CVD-population trial and the TRANSCEND-CKD kidney-disease trial, both Lilly-funded.
What about sleep apnea, knee arthritis, fatty liver?
Lilly is testing all of these, all within its own trial program. TRIUMPH-1 and -2 nest sleep apnea and knee osteoarthritis sub-protocols; TRIUMPH-4 is a standalone knee-OA trial. Every one of these is Lilly-sponsored, meaning independent replication won't exist for any of them until outside researchers get access to the molecule after approval.
What will it cost?
Lilly hasn't announced launch pricing. Based on the company's own existing pricing for tirzepatide ($1,349/mo list for Wegovy-equivalent, $349-499/mo for Zepbound via Lilly Direct), a reasonable estimate is $1,000-1,400/month list at launch. Only 13 US states currently mandate insurance coverage for obesity-indication GLP-1 drugs, and employers are actively dropping coverage as costs rise — so "approved" will not mean "affordable" for most people.
Is the "retatrutide" sold online today the real drug?
No. Eli Lilly holds the patent and exclusively manufactures the investigational compound for its own trials. Anything labeled "retatrutide" sold by research-peptide vendors right now is compounded by third parties with unverified purity and potency. Some doctors are reportedly prescribing compounded versions off-label anyway, ahead of any FDA safety review. Buying gray-market is buying a guess.
Smartest play if I want to lose weight today?
Three options consistently emerge from the data: (1) start an FDA-approved, peer-reviewed option like tirzepatide (Zepbound) now — $349-499 direct, ~22.5% weight loss, published safety record; or (2) enroll in a TRIUMPH trial if you're eligible (drug is free, real Lilly molecule, monitored care, and you're contributing to the independent-data gap by participating); or (3) wait for FDA review and independent peer-reviewed publication before deciding on retatrutide specifically. In every case, pair any GLP-1-class drug with resistance training to protect muscle. Talk to a real obesity-medicine physician, not a med-spa or a drug-company-sponsored webinar.
Key Takeaways
- 28.3% claimed weight loss at 12 mg over 80 weeks in Phase 3 TRIUMPH-1 — a genuinely large number, and currently a sponsor press-release number, not yet independently peer-reviewed
- Every trial of this drug is designed, funded, and run by Eli Lilly — the company with $13B/year and rising riding on a positive verdict; there is no independent human-trial data
- Published Phase 2 data shows meaningful lean/muscle mass loss (~20-25% of total weight lost) — a real trade-off the headline number hides, and one Phase 3 hasn't quantified yet
- Largest heart-rate increase (~6.7 bpm) of any drug in this class; no long-term safety data exists for any dose
- Not FDA-approved — NDA filing expected Q4 2026, approval most likely 2027-2028, and not guaranteed
- Projected to launch at $1,000-1,400/month, in a market where insurance coverage for obesity is patchy (13 states mandate it) and roughly two-thirds of lost weight returns if you can't stay on the drug
- Anything sold today labeled "retatrutide" outside the Lilly trial program is compounded and unverified — a gray market that exists because the real drug is patented, unapproved, and expensive